Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 48,600 shares, a drop of 86.2% from the September 30th total of 352,700 shares. Approximately 9.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,210,000 shares, the short-interest ratio is currently 0.0 days.

Bone Biologics Stock Down 0.1 %

Shares of BBLG stock traded down $0.00 during midday trading on Friday, reaching $1.72. 28,129 shares of the company were exchanged, compared to its average volume of 1,625,136. The company’s 50 day moving average price is $1.66 and its two-hundred day moving average price is $1.62. Bone Biologics has a 12 month low of $0.80 and a 12 month high of $10.56.

Bone Biologics (NASDAQ:BBLG) last released its earnings results on Friday, August 9th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.39) by $0.72. On average, analysts forecast that Bone Biologics will post -3.17 earnings per share for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.